Health
Could Coronavirus Variants Boost Pfizer’s Vaccine Sales By 50%? – Motley Fool
Probably not in the way some might think.
Fifteen billion dollars: That’s how much Pfizer(NYSE:PFE)projected last month in its Q4 update that it will make this year from its COVID-19 vaccine, BNT162b2. Sure, the company splits profits equally with its partner, BioNTech(NASDAQ:BNTX), but we’re still talking about a lot of money.
The actual amount will almost surely be even higher. Since Pfizer’s update, the U.S. government has ordered another 100 million doses of BNT162b2. But could Pfizer’s revenue from the vaccine be 50% higher because…
-
General10 hours agoQantas terminal at Melbourne Airport evacuated and flights delayed due to fire
-
Noosa News19 hours agoJane Edmanson hangs up her Gardening Australia hat, reflects on labour of love behind show’s success
-
General24 hours agoCool weather sets cherry crops ‘weeks’ behind schedule in lead-up to Christmas
-
General23 hours ago‘Brumby Bill’ recognising heritage value of wild horses to be scrapped in NSW